论文部分内容阅读
目的 观察固本消瘤胶囊治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法 102例晚期NSCLC住院患者随机分为固本消瘤胶囊加化疗组(A组54例),化疗组(C组48例)。选择拒绝化疗、单纯口服固本消瘤胶囊组(B组96例),进行对照观察。结果 A、B、C组近期有效率分别为16.7％、3.1％、8.4％,A组优于C组,P<0.05,且A、B两组患者在临床症状变化、生活质量方面均优于C组,P<0.05。中位生存期A、B、C组分别为12个月,15个月和9个月。治疗后1、2、3年生存率,A组分别为57.4％、11.1％和3.7％;B组分别为67.7％、9.38％和3.13％;C组1、2年生存率分别为39.6％、4.17％,3年生存率为0。经统计学处理,A组和B组的生存率优于C组,P<0.05。A组的化疗毒副作用较C组明显减轻。结论 固本消瘤胶囊对NSCLC具有一定的客观疗效,主要表现为稳定病灶、提高生活质量、延长生存期;该制剂与化疗联合应用有明显的增效减毒作用。
Objective To observe the clinical efficacy of Gubenxiaojin capsule in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 102 patients with advanced NSCLC admitted to hospital were randomly divided into Gubenxiao tumor capsule and chemotherapy group (54 cases in group A) and chemotherapy group (48 cases in group C). Choose to reject chemotherapy, simple oral Gubenxiao tumor capsule group (96 cases in group B), the control observation. Results The effective rates of A, B and C groups were 16.7%, 3.1% and 8.4% respectively, A group was better than C group, P <0.05, and the clinical symptoms and quality of life of A group and B group were better than that of C group Group C, P <0.05. The median survival time in groups A, B and C was 12 months, 15 months and 9 months respectively. The survival rates at 1, 2 and 3 years after treatment were 57.4%, 11.1% and 3.7% in group A, 67.7%, 9.38% and 3.13% in group A, respectively. The 1- and 2-year survival rates in group C were 39.6% 4. 17%, 3-year survival rate of 0. After statistical analysis, the survival rates of group A and group B were better than those of group C (P <0.05). A group of chemotherapy toxicity than C group significantly reduced. Conclusion Gubenxiao tumor capsule has certain objective effect on NSCLC, mainly manifested as stable lesion, improving quality of life and prolonging survival period. The combined application of Guben Xiaoyu capsule and NSCLC has obvious synergism and attenuation effect.